ACLY inhibitor SB-204990 could not only suppress lipid synthesis and tumor progression but also show a stronger effect in combination therapy with cisplatin by inhibiting the PI3K-AKT pathway and activating the AMPK-ROS pathway (29, 30). Here, AKT1 is linked to neoplasm.